Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL28595430 | 0.91 | TP53 (0.57) | TP53ALDH1A1LMNATSHRFFAR3 | |
| Oxalic Acid SCHEMBL3973877 | 0.86 | TP53 (0.50) | TP53ALDH1A1FFAR3LCKFYN | |
| Isopropyl Alcohol SCHEMBL9737750 | 0.86 | — | — | |
| Isopropyl Alcohol SCHEMBL538205 | 0.86 | TP53 (0.61) | TP53ALDH1A1LMNATSHRFFAR3 | |
| Isopropyl Alcohol SCHEMBL3155394 | 0.86 | TP53 (0.61) | TP53ALDH1A1LMNATSHRFFAR3 | |
| Lactic Acid SCHEMBL9435530 | 0.84 | TP53 (0.85) | TP53ALDH1A1LMNATSHRSLC7A5 | |
| Oxalic Acid SCHEMBL1837929 | 0.84 | TP53 (0.50) | TP53SLC7A5 | |
| Acetic Acid SCHEMBL9659096 | 0.82 | FFAR3 (0.64) | TP53ALDH1A1LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL574619 | 0.82 | FFAR3 (0.64) | TP53ALDH1A1LMNATSHRFFAR3 | |
| Isopropyl Alcohol SCHEMBL15251690 | 0.82 | TP53 (0.57) | TP53ALDH1A1LMNATSHRFFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105161686-B | Rich lithium material of manganese basic unit shape of double-coating and preparation method thereof | 华南师范大学 | 2017-09-15 | — | — | CN | claimed |
| CN-115485276-B | Deuterated AKT kinase inhibitors | 南京正大天晴制药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117964620-A | AKT inhibitors | 南京正大天晴制药有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-115843298-B | Salts and crystal forms of dihydropyrido [2,3-d ] pyrimidinone derivative | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-113272304-B | AKT inhibitors | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115836069-B | Salts of dihydropyrido [2,3-d ] pyrimidinone derivatives, preparation method and application thereof | 南京正大天晴制药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230321108-A1 | UNIT DOSAGE COMPOSITION OF AKT INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230286979-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230271958-A1 | SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4186902-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| CN-101014570-A | Piperidine derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2007-08-08 | — | — | CN | disclosed |
| US-6489322-B1 | BENZOXAZEPINES AS SELECTIVE INHIBITORS OF THE NEURONAL ISOFORM OF NITRIC OXIDE SYNTHASE FOR TREATMENT OF NEURODEGENERATIVE DISEASE | ASTRAZENECA AB (SE) | 2002-12-03 | — | — | US | disclosed |
| EP-0983268-B1 | AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | disclosed |
| CN-1358169-A | N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same | TOYAMA CHEMICAL CO LTD (JP) | 2002-07-10 | — | — | CN | disclosed |
| CN-1314616-A | Imaging element including support and mechanical holder | EASTMAN KODAK CO (US) | 2001-09-26 | — | — | CN | disclosed |
| EP-0983268-A1 | AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | Astra Aktiebolag (SE) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050382-A1 | AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRA AKTIEBOLAG (SE) | 1998-11-12 | — | — | WO | disclosed |
| CN-1178530-A | Compounds having an effect on 5-hydroxytryptamine related systems | LILLY CO ELI (US) | 1998-04-08 | — | — | CN | disclosed |
| US-4863949-A | CARDIOVASCULAR DISORDER TREATMENT | BOEHRINGER MANNHEIM GMBH (DE) | 1989-09-05 | — | — | US | disclosed |
| US-4435048-A | LARGE AREA OPTICAL DISPLAY | ASAHI GLASS COMPANY LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321108-A1 | UNIT DOSAGE COMPOSITION OF AKT INHIBITOR | AKT2, AKT1, PIK3R2 | TP53 1481/4885ALDH1A1 4415/4885LMNA 3471/4885 |
| US-20230286979-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | FH, GRHPR, SDHB | TP53 214/4885ALDH1A1 492/4885LMNA 4812/4885 |
| US-20230271958-A1 | SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE | DCK, DPYD, UCK2 | TP53 1846/4885ALDH1A1 1413/4885LMNA 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.